株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

世界のHIV感染症薬市場・パイプライン分析

Global HIV Infection Drug Market & Pipeline Insight

発行 KuicK Research 商品コード 310627
出版日 ページ情報 英文 1350 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=114.71円で換算しております。

ご注意: DRM (デジタル著作権管理システム) 付PDFになります。制限内容はお問合せください。
Multi-User License: 会社全体での使用権

Back to Top
世界のHIV感染症薬市場・パイプライン分析 Global HIV Infection Drug Market & Pipeline Insight
出版日: 2014年08月18日 ページ情報: 英文 1350 Pages
概要

当レポートでは、世界のHIV感染症薬市場について調査し、市場概要と発症率の状況、FDAとEMAのHIV治療薬開発規制、世界のHIV感染症治療薬パイプライン、HIV臨床パイプライン、および特許分析などをまとめ、お届けいたします。

第1章 世界のHIV感染症薬市場概要

  • 世界のHIV発生率状況
  • 市場概要:世界・地域
  • 臨床パイプラインの概要

第2章 世界のHIV感染症薬市場における力学

  • 期待できる市場促進因子
  • 解決されるべき市場の課題
  • 将来における機会の展望

第3章 HIVワクチン開発のためのFDA規制の枠組み

  • 小児集団用予防的HIVワクチンの開発
  • HIV抵抗データ提出ガイダンス
  • 抗レトロウィルス開発におけるHIV抵抗検査
  • HIV-1幹線:治療用抗レトロウィルス薬の開発

第4章 HIV感染治療用の医薬品開発のためのEMAにおける規制の枠組み

第5章 世界のHIV感染薬の臨床パイプライン:フェーズ・企業・国別

  • フェーズ不明
  • 研究
  • 前臨床
  • 臨床
  • フェーズ0
  • フェーズI
  • フェーズI/II
  • フェーズII
  • フェーズIII
  • フェーズ
  • 登録前
  • 登録済み

第6章 上市済みHIV治療薬の臨床プロファイル:企業・国別

第7章 臨床パイプラインにおける停止・中止になったHIV治療薬:フェーズ・企業・国別

  • 開発報告なし
  • 中止
  • 停止

第8章 競合情勢

  • Antigen Express
  • Bionor Pharma
  • FIT Biotech
  • Gilead Sciences
  • GeoVax
  • GenVec
  • Glaxo Smithkline
  • Immune Response BioPharma
  • Inovio Pharmaceuticals
  • Novartis
  • Sanofi Pasteur
目次

The rate of HIV infection and the number of deaths due to AIDS has been on a declining note at a positive rate across the globe. It has been estimated that the death rate reduced from 2.3 million in 2005 to 1.5 in 2013, with the rates for children being even much lower. A major cause for such drastic changes in the infection rates has been the improved access to antiretroviral drugs and therapy in recent years. The access to these drugs and therapy has improved significantly, particularly in many developing countries where these drugs and treatments were previously not available at all. At present these solutions have been made accessible and affordable also.

However, a major trend observed in this market has been that although the HIV infection rates are falling, the number of new patients being affected by the virus is increasing. With all the conscious efforts undertaken by all the related organizations and stakeholders, it is expected that by 2015, significant investments would be recorded in this field with the WHO setting an aim to treat close to 15 million HIV patients.

In terms of the market, with the rising popularity of this disease and the growing efforts to combat its spread, it is most likely that an increasing number of companies would enter this market, which would, in the long run, reduce the overall cost of drugs owing to increased competition among the players. Additionally, economies of scale would also be a major factor driving down the cost of drugs targeted for the HIV virus infected people. This in turn would make the drugs and treatment options more affordable.

It is expected that in the next 5-8 years, the pharmaceutical companies would focus more on the development of a successful efficient vaccine to control the spread of this disease. The allocation of resources should necessarily reflect ongoing, strategic prioritization of candidates in the pipeline. With the progress of trials and accumulation of information on the safety and efficacy of new products, there is an urgent demand for strategizing the product pipelines and the prioritization of the decisions. There needs to be complete scrutiny of every single technological area of HIV prevention R&D so as to reflect the best methods of channelizing the funds which are limited in nature. The funds need to be specifically directed towards only those products and approaches which have a high probability of succeeding, instead of those which are less promising.

"Global HIV Infection Drug Market & Pipeline Insight" Report Highlight:

  • Global HIV Infection Drug Market Overview & Incidence Scenario
  • FDA & EMA Regulation for Development of HIV Drug
  • Global HIV Infection Drug Clinical Pipeline by Phase, Company & Country
  • Global HIV Clinical Pipeline: 315 Drugs in Development Phases
  • Majority HIV Drug in Preclinical Phase: 144 Drugs
  • Marketed HIV Drugs: 37
  • Suspended & Discounted HIV Drug in Clinical Pipeline: 539 Drugs
  • Patent Analysis: Patent Number & Technology

Table of Contents

1. Global HIV Infection Drug Market Overview

  • 1.1 Global HIV Incidence Scenario
  • 1.2 Market Overview: Global & Regional
  • 1.3 Clinical Pipeline Overview

2. Global HIV Infection Drug Market Dynamics

  • 2.1 Favorable Market Drivers
  • 2.2 Market Challenges to be Resolved
  • 2.3 Future Opportunity Outlook

3. FDA Regulatory Framework for Development of HIV Vaccine

  • 3.1 Development of Preventive HIV Vaccines for Use in Paediatric Populations
  • 3.2 Guidance for Submitting HIV Resistance Data
  • 3.3 HIV Resistance Testing in Antiretroviral Drug Development
  • 3.4 HIV-1 Infection: Developing Antiretroviral Drugs for Treatment

4. EMA Regulatory Framework for Development of Medicinal Products For Treatment Of HIV Infection

5. Global HIV Infection Drug Clinical Pipeline by Phase, Company & Country

  • 5.1 Phase Unknown
  • 5.2 Research
  • 5.3 Preclinical
  • 5.4 Clinical
  • 5.5 Phase-0
  • 5.6 Phase-I
  • 5.7 Phase-I/II
  • 5.8 Phase-II
  • 5.9 Phase-III
  • 5.10 Preregistration
  • 5.11 Registered

6. Marketed HIV Drug Clinical Profile by Company & Country

7. Suspended & Discontinued HIV Drugs in Clinical Pipeline by Phase, Company & Country

  • 7.1 No Development Reported
  • 7.2 Discontinued
  • 7.3 Suspended

8. Competitive Landscape

  • 8.1 Antigen Express
  • 8.2 Bionor Pharma
  • 8.3 FIT Biotech
  • 8.4 Gilead Sciences
  • 8.5 GeoVax
  • 8.6 GenVec
  • 8.7 Glaxo Smithkline
  • 8.8 Immune Response BioPharma
  • 8.9 Inovio Pharmaceuticals
  • 8.10 Novartis
  • 8.11 Sanofi Pasteur
  • Figure 1-1: People Living With HIV Infection (Million), 2009-2014
  • Figure 1-2: New Incidence of HIV Infection (Million), 2009-2012
  • Figure 1-3: People Living With HIV Infection by Region (%), 2012
  • Figure 1-4: People Accessing Treatment for HIV Infection (Million), 2009-2012
  • Figure 1-5: Global - HIV/AIDS Therapeutics Market (US$ Billion), 2013-2018
  • Figure 1-6: Global - HIV Infection Drug Pipeline by Phase (%), 2014
  • Figure 1-7: Global - HIV Infection Drug Pipeline by Phase (Number), 2014
  • Figure 1-8: Global - No Development Reported in HIV Infection Drug in Pipeline by Phase (%), 2014
  • Figure 1-9: Global - No Development Reported in HIV Infection Drug in Pipeline by Phase (Number), 2014
  • Figure 1-10: Global - Discontinued HIV Infection Drug in Pipeline by Phase (%), 2014
  • Figure 1-11: Global - Discontinued HIV Infection Drug in Pipeline by Phase (%), 2014
  • Figure 1-12: Global - Suspended HIV Infection Drug in Pipeline by Phase (%), 2014
  • Figure 1-13: Global - Suspended HIV Infection Drug in Pipeline by Phase (%), 2014
Back to Top